

1 **Arrayed Imaging Reflectometry monitoring of anti-viral antibody production throughout**
2 **vaccination and breakthrough Covid-19**

3 Alanna M. Klose^{a,b,#}, Gabrielle Kosoy^{a,c,#}, and Benjamin L. Miller^{a, b, c, d, e}

4 ^aDepartment of Dermatology, University of Rochester, Rochester, New York 14627, USA

5 ^bProgram in Materials Science, University of Rochester, Rochester, New York 14627, USA

6 ^cDepartment of Biophysics and Biochemistry, University of Rochester, Rochester, New York
7 14627, USA

8 ^dDepartment of Biomedical Engineering, University of Rochester, Rochester, New York 14627,
9 USA

10 ^eInstitute of Optics, University of Rochester, Rochester, New York 14627, USA

11 #Co-first authors

12

13 **Abstract**

14 Immune responses to COVID-19 infection and vaccination are individual and varied. There is a
15 need to understand the timeline of vaccination efficacy against current and yet to be discovered
16 viral mutations. Assessing immunity to SARS-CoV-2 in the context of immunity to other
17 respiratory viruses is also valuable. Here we demonstrate the capability of a fully automated
18 prototype Arrayed Imaging Reflectometry (AIR) system to perform reliable longitudinal serology
19 against a 34-plex respiratory array. The array contains antigens for respiratory syncytial virus,
20 seasonal influenza, common human coronaviruses, MERS, SARS-CoV-1, and SARS-CoV-2.
21 AIR measures a change in reflectivity due to the binding of serum antibodies to the antigens on
22 the array. Samples were collected from convalescent COVID-19 donors and individuals

23 vaccinated with a two-dose mRNA vaccine regimen. Vaccinated samples were collected prior to
24 the first dose, one week after the first dose, one week after the second dose, and monthly
25 thereafter. Information following booster dose and/or breakthrough infection is included for a
26 subset of subjects. Longitudinal samples of vaccinated individuals demonstrate a rise and fall of
27 SARS-CoV-2 spike antibodies in agreement with general knowledge of the adaptive immune
28 response and other studies. Linear Regression analysis was performed to understand the
29 relationship between antibodies binding to different antigens on the array. Our analysis
30 identified strong correlations between closely related influenza virus strains as well as
31 correlations between SARS-CoV-2, SARS-CoV-1, and human coronavirus 229E. A small test
32 of using diluted whole blood from a fingerstick provided clean arrays with antibody binding
33 comparable to serum. Potential applications include assessing immunity in the context of
34 exposure to multiple respiratory viruses, clinical serology, population monitoring to facilitate
35 public health recommendations, and vaccine development against new viruses and virus
36 mutations.

37

38 **Introduction**

39 As we are all well aware, the COVID-19 pandemic, caused by the SARS-CoV-2 virus,
40 challenged the social and economic stability of the world since emerging in late 2019 [1]. It
41 motivated the rapid expansion and development of diagnostic methods for identifying infection,
42 including nucleic acid, antigen, and antibody detection [2]. The deployment of safe and effective
43 vaccines in late 2020 changed the course of the pandemic by reducing the severity of disease
44 and suggested the possibility that immunity would be maintained by a future endemic status
45 [3,4]. The virus has subsequently mutated to produce variants of concern (VOCs) that have
46 caused waves of breakthrough infections [5]. A third dose of BNT162b2, the mRNA vaccine
47 developed by Pfizer, has been shown to improve immunity to the omicron variant BA.1 by

48 increasing the neutralizing capability of circulating IgGs [6,7]. Data from a study of a fourth
49 BNT162b2 vaccine dose in Israel suggests that the doubly boosted immune response lasts less
50 than or equal to two months in individuals over 60 years of age [8]. As governments worldwide
51 have begun to embrace an endemic future of COVID-19 it will be important to track immune
52 responses to VOCs in vaccinated individuals to inform decisions about mask wearing, booster
53 doses for healthy and immunocompromised individuals, and development of VOC-specific
54 vaccines [9].

55 Cross-reactive antibodies against common human coronaviruses (hCoVs), SARS-CoV-1, and
56 MERS are increased after COVID-19 infection [10], and to a lesser extent vaccination [11,12].
57 However, the role of pre-existing cross-reactive T-cells and antibodies to hCoVs in protection
58 against Covid-19 is controversial, with some studies reporting enhanced immune responses
59 [13,14], and others reporting no protection [15] or even a decreased immune response [16]. The
60 ability to evaluate cross-reactive antibody binding to hCoV antigens, SARS-CoV-1, MERS, and
61 SARS-CoV-2 antigens with a single test could enable further exploration into the relationship
62 between cross-reactivity of the antibodies and disease outcome.

63 Influenza surveillance around the world currently relies on either RT-PCR or rapid tests. Rapid
64 tests only indicate the presence of Influenza A or B, not subtype or individual strain. RT-PCR
65 can test for subtype and strain but requires primers for each strain that is being tested for [17].
66 Tracking which strains of influenza are circulating or are closely cross-reactive is important for
67 vaccine development and outbreak prediction [18].

68 For several years, we have worked to develop array-based methods based on Arrayed Imaging
69 Reflectometry (AIR) for rapidly assessing immunity to upper respiratory viruses [19]. AIR relies
70 on the quantitative perturbation of a near-perfect antireflective condition on a silicon/silicon
71 dioxide chip as targets bind to the arrayed probes [20,21]. As an imaging technique, AIR can
72 quantify binding of more than 100 targets on an array independently and simultaneously [22]. In

73 previous work, we developed an AIR array suitable for monitoring the immune response to
74 SARS-CoV-2, and demonstrated multiplex data consistent with single-analyte ELISA [23]. Here,
75 we have employed a prototype commercial version of AIR, which requires only a few microliters
76 of each serum sample or whole blood, with a significantly expanded array of recombinant
77 proteins (antigens) from upper respiratory viruses. We demonstrate the use of AIR to screen for
78 antibodies against antigens from 34 human respiratory viruses including SARS-CoV-2, SARS-
79 CoV-1, MERS, common hCoVs, and pandemic and seasonal influenza strains of type A and B.
80 This is a longitudinal study of adult subjects who were infected with SARS-CoV-2, received a
81 Pfizer/BioNTech (BNT162b2) or Moderna (MRNA-1273) vaccine, or experienced both infection
82 and vaccination. Vaccinated samples were collected prior to the first dose, one week after the
83 first dose, one week after the second dose. In some individuals we were able to obtain samples
84 monthly for up to 6 months after the second vaccine dose, and two weeks after a breakthrough
85 infection.

86 This 34-plex array generates 561 combinations of probes, which creates an opportunity to
87 evaluate relationships between antibody responses between probe antigens. Linear regression
88 provides a single numerical measure (coefficient of determination, R^2 value) of the influence that
89 one variable has on the other. This analysis helps us quantify the impact that the Pfizer and
90 Moderna vaccines, which consist of mRNA encoding the full-length SARS-CoV-2 spike protein
91 [24,25], had on the immune response to other SARS-CoV-2 antigens, including the D614G
92 mutation, as well as related SARS-CoV-1, MERS, and hCoV proteins. This could help identify
93 cross-reactive binding of antibodies to new variants or identify when vaccines need to be
94 modified to improve immune response. Although the arrays tested here are commercially
95 produced, the technology allows for easy modification to add new Covid-19 or influenza VOCs
96 as they arise.

97

98

99 **Materials and Methods**


100 *Human Samples*

101 For serum collection, whole blood was drawn via venipuncture, allowed to clot at ambient
102 temperature for at least 1 hour, and then centrifuged at 1200 x g for 15 min. Serum was drawn
103 off via pipette, aliquoted, and stored at -80 °C prior to use. Sera were drawn under protocols
104 approved by the University of Rochester Medical Center Institutional Review Board for
105 dermatology department assay development. Whole blood assays were performed using
106 pressure activated safety lancets to prick the subject's finger and pipette 3 µL of blood. Blood
107 was immediately diluted and used in the assay as described below. Sample IDs used in this
108 manuscript were not known to any personnel outside the research group.

109 *ZIVA by Adarza Biosystems, Inc.*

110 ZIVA is an automated version of AIR produced in prototype form by Adarza Biosystems,
111 formerly St. Louis, MO. While Adarza has ceased operations, the methods and results
112 described here are consistent with and transferrable to other AIR instrumentation developed in
113 our laboratory. The ZIVA platform consists of 96-well plates of individually packaged pre-
114 arrayed AIR chips in custom-designed cartridges for sample addition and a fully automated
115 instrument for processing the cartridges through washing, imaging, and data processing (Fig 1).
116 Cartridges came in an Acute Respiratory Virus Array (ARVA) kit also purchased from Adarza
117 Biosystems. Each cartridge accepts 45 µL of sample, which is easily applied using standard
118 multichannel pipettes. In this study, all serum samples were diluted 1:20 in Assay Wash Buffer
119 (AWB: mPBS with 0.005% tween-20, pH 7.2) containing 20% Fetal Bovine Serum (FBS), which
120 means that 3 µL of serum is required for the assay. The samples were added to the cartridges
121 and allowed to incubate for 1 hour at RT, shaking at 420 RPM, plus 2 hours at RT without

122 shaking. The 2 extra hours are not necessary, but were added due to technical difficulties with
123 the prototype instrument during the first group of samples, and were retained for consistency
124 throughout the study. The plate was then loaded into the instrument and processed.



125

126 **Fig 1. ZIVA system including 96-well plate full of AIR chip cartridges and fully automated**
127 **instrument.**

128 *Data Processing*

129 AIR provides reflectivity data in an image, where the intensity of each pixel may be converted to
130 thickness via well-established algorithms [21]. Thickness in turn may be converted to
131 concentration if desired with reference to a calibration curve. While the ZIVA instrument has its
132 own software that provides both numerical and graphical results, it also has an option to provide
133 raw reflectivity and converted thickness data in a csv file. The data shown here are the
134 converted thicknesses from that raw csv file which were extracted and organized using custom
135 Matlab [26] and R [27]/R Studio [28] scripts. Heatmaps report thickness change in Ångstroms
136 (Å), and were generated using Pandas [29] and Seaborn [30]. Data preprocessing and plotting
137 were done using tidyverse [31]. Linear regression analysis was done using the stats package
138 and ggpmisc [32]. The thickness change is calculated by subtracting the thickness of each

139 probe on a negative control chip, also referred to as a blank (exposed only to AWB with 20%
140 FBS) from each probe on a sample chip. The limit of detection (LOD) was calculated for each
141 antigen using the raw thickness data from 4 negative control chips (n=4) run on the array when
142 the kit was first opened. The limit of detection was calculated at the mean thickness of the blank
143 chips (μ_{blank}) plus 3 times the standard deviation of the blank chips (SD_{blank}).

$$144 \quad \quad \quad LOD = \mu_{blank} + 3 \times SD_{blank}$$

145 Only those thickness changes above the LOD for each antigen were applied toward linear
146 regression analysis of relationships between antigen responses on the array. Furthermore, any
147 linear regression model with a p-value <0.01 was considered insignificant.

148 The instrument does not require processing a full plate of samples at a time, and therefore
149 partial plates were used throughout the study in an attempt to preserve available cartridges.
150 This also meant that some samples were processed 6 months after the kit was opened, which
151 resulted in some loss of signal on the array. In these cases, linear regression analysis between
152 samples run on “initial” and “decayed” cartridges was used to generate an equation used to
153 calculate the adjusted thickness changes (Fig S1). In the interest of transparency, the
154 unadjusted thickness changes of all vaccination samples are included in Fig S2.

155

156 **Results and Discussion**

157 An early 16-plex version of the ARVA was used for initial experiments (Table 1). The samples
158 beginning with ‘SN’ were drawn from subjects who had had an unknown respiratory illness at
159 some time during late 2019 and early 2020. This was early in the pandemic when tests were in
160 short supply, and only SN028 had a PCR-confirmed case of Covid-19. The ‘HD’ samples were
161 acquired at least 14 days after illness from convalescent COVID-19 patients via the University of
162 Rochester Medical Center’s Healthy Donor protocol.

163 **Table 1. Antigens on an early 16-plex ARVA.**

Preliminary Acute Respiratory Viral Serology Array-16 Plex	
Influenza A and B	FluA H1N1 CA 09
5 unique targets	FluA H3N2 WI 05
	FluB FL 06
	FluB MA 10
	FluB UT 12
Common Coronavirus 3 types	COV 229E S1S2
	HCOV HKU1 S1S2
	HCOV OC43 S1S2
MERS CoV 2 antigen targets	MERS RBD
	MERS S1
SARS CoV-1	SARS S1
SARS CoV-2 5 antigen targets	SARS2 N
	SARS2 RBD
	SARS2 S1
	SARS2 S1S2
	SARS2 S2

164

165 The heatmap in Fig 2 shows antibody binding onto each antigen in the array as a thickness
166 change relative to the control chip (build). We can see varied responses to influenza and
167 common hCoV antigens across individuals, which is expected due to personal health histories
168 and propensity to receive annual flu shots. When looking at the SARS-CoV-2 antigens we see
169 that many, but not all the convalescent patients have antibodies in their serum that bind to N-
170 protein and spike proteins including the receptor binding domain (RBD) as well as full length
171 S1+S2 and individual subunits S1 and S2. This is consistent with work performed on these
172 samples in our laboratory with the preliminary, non-automated version of a SARS-CoV-2 AIR
173 array [23], and with ELISA results on these samples acquired by an independent laboratory [33].
174 The low SARS-CoV-2 antibody responses in some convalescent patients can be explained by
175 some patients self-reporting illness without a positive PCR test. Assuming that all “SN” samples
176 were uninfected with SARS-CoV-2 with the exception of SN028 (known PCR positive), these
177 values excluding those from SN028 were averaged together into the uninfected group in Fig S3.
178 All HD patients plus SN028 were grouped into the convalescent group. When comparing
179 average antibody build across all convalescent patients to all uninfected patients, there is


180 significantly more antibody binding onto all SARS-CoV-2 antigens in convalescent serum
181 (unpaired, 2-tailed t-test assuming unequal variance). There is also a significant increase in
182 cross-reactive antibody binding to the SARS-CoV-1 S and OC43 S1S2, but not to MERS S1.
183 The significant increase in cross-reactive antibodies against OC43 after infection with COVID-19
184 is consistent with the ELISA results from the same convalescent samples [33]. Interestingly, that
185 same group provided evidence that hCoV memory B cells against OC43 were activated in
186 response to infection with SARS-CoV-2.



188 **Fig 2. Heatmap of thickness change per array protein.** Samples were from convalescent
189 COVID-19 patients (HD) and study subjects (SD) with unknown COVID-19 illness history.

190
191 To understand the quantitative range of the assay we selected five high responding
192 convalescent samples and performed serial serum dilutions of 1:20, 1:40, 1:80, 1:160, and
193 1:320 (Fig 3). Here the data are reported as simply thickness (\AA) where negative control
194 information is not subtracted but is instead plotted independently. The standard deviation of
195 serum samples was calculated from replicate probe spots on each array [21]. Positive samples
196 were determined as those significantly different from control by one-tailed two-sample t-test with
197 $p < 0.01$. The sample dilutions were all analytically well-behaved and titrated to zero. While the

198 creation of a standard curve to convert thickness change to antibody concentration was not
199 within the scope of this study, these data suggest that it would be possible to measure protein
200 concentration using the ZIVA platform.



201
202 **Fig 3. Serial dilutions of selected convalescent serum samples.** Dilutions were two-fold
203 (1:20, 1:40, 1:80, 1:160, 1:320) on serum samples HD2134, HD2136, HD2138, HD2141, and
204 HD2145. Positive samples are significantly different from the negative control sample by t-test, p
205 < 0.1 .


206
207 An expanded 34-plex ARVA kit (Table 2) was used for longitudinal studies of vaccinated
208 individuals (designated VN) in order to track immune response over time. The array generates a
209 large amount of data, making a heatmap the most effective way to gain an overview of the
210 range of responses per sample (Fig 4). The hue indicates thickness change relative to a control
211 chip per antigen on the array per sample, with darker blue indicating a larger thickness change
212 as more antibody bound to antigen.

213 **Table 2. Antigens on a 34-plex ARVA.**

Acute Respiratory Viral Serology Array-34 Plex

RSV	RSV A Glycoprotein
2 types	RSV B Glycoprotein
Influenza A and B	Influenza A H1N1 (4 origins: California 04/2009, California 07/2009, Beijing, Guangdong-Maonan)
17 unique targets	Influenza A H3N2 (5 origins: Wisconsin, Texas, Hong Kong 2014, Hong Kong 2019, Switzerland)
	Influenza A H7N9 (Shanghai)
	Influenza A H5N1 (Vietnam)
	Influenza B (6 lineages: Massachusetts, Phuket, Malaysia, Florida, Brisbane, Washington)
Common Coronavirus	HCoV-229E
4 types	HCoV-HKU1
	HCoV-NL63
	HCoV-OC43
MERS CoV	Nucleocapsid
3 antigen targets	Receptor Binding Domain (RBD)
	Spike S1
SARS-CoV-1	Receptor Binding Domain (RBD)
2 antigen targets	Spike S1
SARS-CoV-2 (COVID-19)	Nucleocapsid
6 antigen targets	Receptor Binding Domain (RBD)
	Spike S1
	Spike S1+S2 ECD
	Spike S2 ECD
	Spike S1 D614G mutant variant

214



215

216 **Fig 4. Thickness Change per array protein in vaccinated subjects.** Thickness change is
217 representative of antibodies binding to antigens on the 34-plex array for longitudinal serum
218 samples collected from vaccinated subjects.

219 As expected based on recent studies of time-dependent antibody titers following vaccination
220 [34,35,36,37], the thickness change on the SARS-CoV-2 antigens is dynamic. Looking at VN02,
221 we see that this subject had an increase in SARS-CoV-2 spike antibodies two weeks after the
222 first vaccine dose, which is consistent with other vaccine studies [38]. This pattern holds for
223 other subjects (VN- 01, 03, 04, 05, 17, 25, 27) who also donated serum two weeks after the first
224 dose. Additionally, these observations fit with general knowledge of the adaptive immune
225 response. Our results show that the multiplex ARVA array is able to differentiate subjects who
226 had a covid-19 infection (9, 11, 15, and 16) from those who only received the vaccine, by
227 looking at the thickness change caused by antibodies binding to the N-protein. The N-protein is
228 located inside of the viral envelope and interacts with the viral RNA [39]. Since the vaccine
229 mRNA only encodes the spike protein, there isn't an immune response to N-protein in naïve
230 vaccinated individuals. A few of these subjects (VN- 21, 23, and 30) were taking
231 immunosuppressive medications during the course of the study. While VN23 and VN30 seem to
232 mount immune responses to the vaccine, the same cannot be said of VN21. This is a very small
233 sample size, but suggests that AIR technology and the ARVA array could be used to screen
234 immunosuppressed patients to determine if they need extra vaccine doses, antibody therapy, or
235 if they need to take extra precaution to avoid infection. Likewise, such screening could bring
236 peace of mind to immunosuppressed patients who do generate antibodies in response to
237 vaccination, especially since antibody titer correlates with neutralizing capability and protection
238 against severe disease [40].

239 Antibody response due to vaccination was assessed by grouping samples acquired before
240 vaccination and samples acquired 1-2 weeks after the second vaccine dose (Fig S4). There are


241 significant increases in antibodies binding all SARS-CoV-2 antigens except the N-protein as
242 expected, since the vaccines encode the full-length spike protein, and significant cross-reactive
243 antibodies to SARS-CoV-1 RBD and S1, MERS-CoV-S1, and 229E. Recent work profiling
244 cross-reactive antibodies to related coronaviruses after vaccination of naïve individuals found
245 significant antibody cross-reactivity to SARS-CoV-1 and MERS-CoV spike proteins [12]. Cross-
246 reactivity of antibodies toward common cold hCoVs following vaccination against SARS-CoV-2
247 has also been observed [11]. It seems that most of this cross-reactivity is recognizing conserved
248 epitopes on the S2 subunit of these hCoVs [10,11]. Our array only included the S1 subunit of
249 NL63 and HKU1. This array included the full-length spike protein for OC43, but many of the
250 responses were below the limit of detection for that protein on this version of the array.

251 The build onto the influenza antigens is fairly consistent for many subjects, while others have
252 increases in antibody binding. VN09 received a flu shot prior to the fourth serum sample as
253 noted in the figure. While the 2020-2021 quadrivalent flu shot was designed to activate an
254 immune response against A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus, A
255 A/Hong Kong/2671/2019 (H3N2)-like virus, B/Washington/02/2019-like virus (B/Victoria
256 lineage), and B/Phuket/3073/2013-like virus (B/Yamagata lineage) [41], this individual seemed
257 to mount an immune response to other influenza antigens on the array, which is probably cross-
258 reactivity among influenza strains. This may be the case for other subjects as well, but we lack
259 information about flu shots or illness history to be able to confirm.

260 Even though information about influenza vaccination or infection during the time frame that
261 these samples were collected is not available, there is still an opportunity to look for correlated
262 immune responses to antigens across the array. Linear regression analysis provides an R^2
263 value indicating how much influence one variable has on the other. In this context we are using
264 it to determine the correlation between samples, where a perfect correlation has R^2 equal to 1.
265 Biologically, stronger correlations mean that higher amounts of antibodies binding to the epitope

266 of one protein indicate more antibodies binding to the epitope of the second protein. Linear
267 regression was only performed on thickness change data that was larger than the calculated
268 limit of detection (LOD) for each protein on the array, and only the models with p-values < 0.01
269 were considered representative of a true relationship between variables. Of note, there were no
270 negative correlations between any of the antigens on the array, indicating that vaccination with
271 these SARS-CoV-2 vaccines doesn't negatively affect the immune response to other upper
272 respiratory viruses. As a positive control, we saw that the two pandemic strains of influenza
273 isolated in California in the same year (Cal09) had a correlation of 1 (Fig 5). This is expected
274 because these two proteins have a nucleic acid sequence similarity of 99.9%. We were able to
275 identify how strongly the subtypes, H1N1, H3N2, and influenza B, influenced each other.
276 Proteins of the same subtype showed very strong correlation, with Influenza A Beijing H1N1 and
277 Influenza A California H1N1 07-2009 showing the strongest relationship ($R^2 = 0.96$). Influenza A
278 Texas H3N2 and Influenza A Hong Kong H3N2 2019 were the most strongly correlated H3N2
279 subtypes ($R^2=0.83$). Influenza B Washington 2019 and Influenza B Massachusetts were the
280 most strongly correlated influenza B strains with $R^2=0.83$.

281



282

283 **Fig 5. Selected correlations between proteins by linear regression.** Plots were made with

284 data from samples drawn within two weeks of the second dose of a SARS-CoV-2 mRNA

285 vaccine. Points are individual samples, and lines are linear regressions with a grey band

286 indicating standard deviation.

287 There is a strong correlation between antibody binding to the 229E full length spike protein and

288 SARS2- S2 subunit ($R^2=0.77$) on our array. The alpha-coronavirus 229E has 31% amino acid

289 sequence similarity for the spike protein of beta-coronaviruses SARS-CoV-2 and SARS-CoV-1,

290 particularly in the conserved regions of the spike protein [42]. Titers of 229E antibodies have

291 been shown to increase in convalescent and immunized populations, and antibody binding to

292 229E decreased 71% after depleting the serum with a monomeric SARS-CoV-2 S2 subdomain

293 [11,33].

294 There is also a strong correlation between SARS-CoV-1 RBD and SARS-CoV-2 RBD ($R^2=0.83$).


295 This is expected because these peptides share 74% amino acid sequence identity [43]. The

296 D614G spike mutation became widespread after March 2020 [44]. Studies of the structure of the

297 S1 and D614G S1 variant indicate that the D614G variant could have more antibody binding
298 due to having a more flexible S1-S2 interface [45]. Antibody neutralization studies have shown
299 slightly more antibody neutralization against the D614G variant [46]. On our array, D614G S1
300 protein is observed to have more binding overall than the wild-type S1 (Fig S4), and the
301 correlation between them is very strong ($R^2=0.93$) (Fig 5). Many antibody-binding responses are
302 the array were not strongly correlated. For example, SARS-CoV-2 RBD and Influenza A Beijing
303 hemagglutinin do not have a strong relationship, which is expected because these viruses are
304 phylogenetically distinct.

305 Comparing antibody responses across all of the proteins on our array from longitudinal samples
306 enables comparisons of antibody duration and waning. Fig 6 presents SARS-CoV-2 RBD and
307 influenza strain A/California/07/2009 hemagglutinin protein antibody levels over time. The
308 individuals included in this analysis met the criteria of having a baseline sample collected
309 immediately before receiving the vaccine and samples collected one week after first dose and
310 one week after second dose of vaccine. Some individuals also went on to have monthly blood
311 draws thereafter. Most of these individuals had not been infected with Covid-19 prior to this
312 study, with the exception of VN11. Circulating SARS-CoV-2 RBD antibody levels in VN11 were
313 initially higher than the other, naïve subjects shown in this figure, and immediately increased
314 one week after receiving the first vaccine dose. The naïve subjects did not show an increase in
315 circulating antibodies against SARS-CoV-2 RBD one week after the first vaccine dose, but had
316 a robust response after the second dose, which is consistent with findings from clinical trials
317 [34,35]. The waning of SARS-CoV-2 RBD antibodies over time agrees with other studies
318 showing circulating antibody levels returning close to baseline after 6 months or around 200
319 days [47]. At day 0, the variance in the number of antibodies present against influenza is greater
320 than against SARS-CoV-2 RBD, but the overall level of influenza antibodies was significantly
321 higher. This was expected because these strains of influenza infections and vaccines have

322 been circulating for over a century, and most if not all individuals have been exposed to them
323 throughout their lifetimes. In contrast, SARS-CoV-2 is a new strain of coronavirus. People who
324 receive influenza vaccinations generally retain influenza-specific IgG antibodies for around two
325 years [48], and cross-reactive antibodies to other strains will make this appear higher.




326

327 **Fig 6. Antibody duration and waning following COVID-19 vaccination.** The eleven subjects
328 plotted here (coded by color) all followed the criteria of having a baseline sample collected
329 before receiving the vaccine and samples collected one week after first dose and one week
330 after second dose of vaccine. Day 0 is the baseline value. Circulating antibodies against the
331 SARS-CoV-2 RBD protein increased with vaccination and decayed over time. Antibody
332 response against the influenza strain A/California/07/2009 hemagglutinin protein had larger
333 variance between samples and response remained similar over time.

334

335 A subset of subjects who received a booster vaccine dose or had a breakthrough infection is
336 shown in Fig 7. Circulating antibody levels increase from first to second dose, followed by a


337 slow decline over the following six months, and a sharp increase after booster or breakthrough
338 infection. Subjects VN04 and VN09 both had breakthrough infections. Although we expected to
339 see antibodies against the N-protein after infection in both samples, this was not the case for
340 VN04. A low humoral response of antibodies against the N-protein in a fraction of individuals
341 after infection has been observed in other studies [49,50], and younger people with
342 asymptomatic or mild cases tend to produce lower antibody titers against the N-protein [51].
343 Subject VN09 (a female, under 40, with a mild case of COVID-19) is intriguing because she had
344 a mild PCR-confirmed case of COVID-19 before receiving the vaccine, but didn't have a robust
345 antibody response to the N-protein until after breakthrough infection. Her second infection
346 seemed to boost her initially low immune response towards the N-protein.



347
348 **Fig 7. Heatmap of thickness change for SARS-CoV-2 proteins in COVID-19 vaccinated**
349 **subject serum.** Subjects received a booster shot or had a breakthrough infection. Black arrows
350 indicate vaccine doses. Red arrows indicate infection (“I” for infection prior to vaccine, and “B”
351 for breakthrough infection).

352
353 The small volume requirements of the ZIVA AIR system make it possible to do a whole blood
354 assay using only a fingerstick volume of blood (3 μ L). An initial test produced clean arrays that
355 were comparable to serum in both background and target reflectivity (Fig 8A). The serum and

356 the blood were from the same individual, who had a breakthrough case of COVID-19 confirmed
357 by a positive commercial antigen test. The thickness change on cytC (negative control antigen)
358 and FluA/HK/H3N2/19 was identical between the serum and whole blood. The serum was
359 collected 5 weeks prior to the whole blood sample, so the decrease in circulating antibodies
360 against SARS-CoV-2 in the whole blood sample compared to serum is consistent with that seen
361 in figures 4,6, and 7 (Fig 8B).



362

363 **Fig 8. Whole blood assay.** (A) Arrays incubated with serum vs. 3 μ L whole blood from the
364 same individual. Serum sample was drawn 5 weeks prior to whole blood sample. (B) Thickness
365 increase for three antigens on the array. Error bars are standard deviation of replicate spots of
366 each protein on an array.

367 Conclusion

368 In this study, we have demonstrated that a prototype automated version of the label-free AIR
369 sensor technology is able to profile human antibody responses to 34 antigens from upper
370 respiratory viruses including SARS-CoV-2 from a small (<10 μ L) sample of serum or whole
371 blood. Of particular current interest, this approach proved useful in providing insight into immune
372 responses following Covid-19 infection and vaccination. The results were consistent with

373 previous low-multiplex work performed by our lab and with findings elsewhere. Given that AIR is
374 expandable to include 100 or more probes, we can envision future work in which antigens from
375 new SARS-CoV-2 variants are added to the array as they arise. For example, we know now that
376 the booster dose can improve antibody neutralization of the Omicron variant [6,7], but it is not
377 currently known how well existing immunity will adapt to future variants. We expect our tool will
378 be useful to help predict vaccinated immune responses to newly discovered VOCs before they
379 become widespread. Multiplex AIR technology could also be useful for influenza and
380 coronavirus surveillance and could ease further investigation into the relationship between
381 antibody cross-reactivity and disease outcome. Finally, the ability to use a fingerstick quantity of
382 blood to generate a real-time profile of circulating antibodies could be useful as a clinical
383 diagnostic technique. Studies along these lines are currently in progress in our laboratory.

384 Acknowledgement: This research was supported by the New York State Empire State
385 Development Fund, and by the U.S. Department of Defense under AIM Photonics, Air Force
386 Contract FA8650-15-2-5220. The views and opinions expressed in this paper are those of the
387 authors and do not reflect the official policy or position of the United States Air Force,
388 Department of Defense, or the U.S. Government. We thank Professor Matthew Brewer,
389 Professor Mark Sangster, and Micah Wiesner for helpful discussions in immunology, virology,
390 data analysis, and programming

391

392 References

¹ United Nations Department of Economic and Social Affairs [Internet]. Everyone Included:
Social impact of COVID-19. [cited 2022 Apr 7]. Available from:
<https://www.un.org/development/desa/dspd/everyone-included-covid-19.html>.

² Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Abo El-Ella DM, et al. Emerging COVID-19 variants and their impact on SARS CoV-2 diagnosis, therapeutics and vaccines. *Infect Dis.* 2022;54:524-540.

³ Veldhoen M, Simas JP. Endemic SARS-CoV-2 will maintain post-pandemic immunity. *Nat Rev Immunol.* 2021;21:131-132.

⁴ Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. *Science.* 2021 Jan;371(6530):741-745.

⁵ Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-Cov-2 variants, spike mutations, and immune escape. *Nat. Rev. Microbiol.* 2021;19:409-424.

⁶ Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nat Med.* 2022;28:477-480.

⁷ Muecksch F, Wang Z, Cho A, Gaebler C, Tanfous TB, DaSilva J, et al. Increased potency and breadth of SARS-CoV-2 neutralizing antibodies after a third mRNA vaccine dose. *BioRxiv* [Preprint]. 2022 [cited 2022 Apr 13]. Available from: <https://www.biorxiv.org/content/10.1101/2022.02.14.480394v1> doi: 10.1101/2022.02.14.480394.

⁸ Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. *N Engl J Med.* 2022 May;386:1712-1720.

⁹ Centers for Disease Control and Prevention [Internet]. SARS-CoV-2 Variant Classifications and Definitions [updated 2022 Apr 26; cited 2022 July 28]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html>

¹⁰ Embong AK, Nguyen-Contant P, Wang J, Kanagaiah P, Chaves FA, Fitzgerald TF, et al. Formation and expansion of memory B cells against coronavirus in acutely infected Covid-19 individuals. *Pathogens.* 2022 Jan;11(186). Available from: <https://doi.org/10.3390/pathogens11020186>.

- ¹¹ Grobden M, van der Straten K, Brouwer P.J, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, et al. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. *eLife*. 2021 Nov;10:e70330. Available from: <https://elifesciences.org/articles/70330>.
- ¹² Geanes ES, LeMaster C, Fraley ER, Khanal S, McLennan R, Grundberg E, et al. Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination. *Sci.Rep.* 2022;12:6496.
- ¹³ Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. *Science*. 2021 Oct;374(6564) Available from: <https://www.science.org/doi/10.1126/science.abh1823> doi: 10.1126/science.abh1823.
- ¹⁴ Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Comm.* 2022 Jan; 80. Available from: <https://doi.org/10.1038/s41467-021-27674-x>.
- ¹⁵ Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell*. 2021 Apr; 184(7): 1858-1864.e10.
- ¹⁶ Lin C, Wolf J, Brice DC, Sun Y, Locke M, Cherry S, et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. *Cell Host Microbe*. 2022 Jan; 30(1):83-96.e4.
- ¹⁷ Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, et al. Influenza. *Nat Rev Dis Primers*. 2018 Jun;4(3). Available from: <https://doi.org/10.1038/s41572-018-0002-y>.
- ¹⁸ Centers for Disease Control and Prevention. Overview of Influenza Surveillance in the United States. [updated 2021 Oct 15, cited 2022 July 19]. Available from: <https://www.cdc.gov/flu/weekly/overview.htm>.

- ¹⁹ Bucukovski J, Latorre-Margalef N, Stallknecht DE, Miller BL. A multiplex label-free approach to avian influenza surveillance and serology. PLoS ONE. 2015;10(8):e0134484.
- ²⁰ Mace CR, Striemer CC, Miller BL. Theoretical and experimental analysis of arrayed imaging reflectometry as a sensitive proteomics technique. Anal Chem. 2006;78(15):5578-83.
- ²¹ Klose AM, Daiss JL, Ho L, Beck CA, Striemer CC, Muthukrishnan G, Miller BL. StaphAIR: A label-free antigen microarray approach to detecting anti-*Staphylococcus aureus* antibody responses in orthopedic infections. Anal Chem. 2021;93(40):13580-13588.
- ²² Zhang H, Henry C, Anderson CS, Nogales A, DeDiego ML, Bucukovski J, et al. Crowd on a chip: Label-free human monoclonal antibody arrays for serotyping influenza, Anal Chem. 2018;90:9583-9590.
- ²³ Steiner DJ, Cognetti JS, Luta EP, Klose AM, Bucukovski JB, Bryan MR, et al. Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients. Biosens Bioelectron. 2020;169:112643.
- ²⁴ Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020;383:2603-2615.
- ²⁵ Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403-416.
- ²⁶ MATLAB (2020). version 9.8.0 (R2020a). Natick, Massachusetts: The MathWorks Inc.
- ²⁷ R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: <https://www.R-project.org/>.
- ²⁸ RStudio Team (2021). RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA. Available from: <http://www.rstudio.com/>.
- ²⁹ McKinney WM, & others., Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in Science Conference 2010;445:51-56.
- ³⁰ Waskom, M. L. Seaborn: statistical data visualization. J Open Source Softw. 2021;6(60). Available from: <https://doi.org/10.21105/joss.03021>.

³¹ Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the tidyverse. *J Open Source Softw*. 2019;4(43):1686 Available from:

<https://joss.theoj.org/papers/10.21105/joss.01686>.

³² Pedro J. Aphalo. (2016) Learn R ...as you learnt your mother tongue. Leanpub, Helsinki.

Available from: <https://leanpub.com/learnr>.

³³ Nyguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, et al. S

Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection

Includes Broad Reactivity to the S2 subunit. *mBio*. 2020 Sep 20; 11(5). Available from:

<https://journals.asm.org/doi/10.1128/mBio.01991-20>.

³⁴ Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. *N Engl J Med*. 2020;383:2439-2450.

³⁵ Chu L, MePhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine*. 2021;39(20):2791-2799.

³⁶ Demonbreun AR, Sancilio A, Velez MP, Ryan DT, Saber R, Vaught LA, et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. *EClinicalMedicine*. 2021;38. Available from:

<https://doi.org/10.1016/j.eclinm.2021.101018>.

³⁷ Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 months. *N Engl J Med*. 2021;385:e84.

³⁸ Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential antibody response to mRNA covid-19 vaccines in healthy subjects. *Microbiol Sepctr*. 2021;9:e00341-21.

³⁹ Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. *Methods Mol Biol*. 2015;1282:1–23.

- ⁴⁰ Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng, W, et al. Immune correlates analysis of the mRNA-1273 covid-19 vaccine efficacy clinical trial. *Science*. 2021;375(6576):43-50.
- ⁴¹ U.S. Food & Drug Administration. Influenza Vaccine for the 2020-2021 season. [updated 2021 Feb 24, cited 2022 Apr 12]. Available from: <https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2020-2021-season>.
- ⁴² Jacob-Dolan C, Feldman J, McMahan K, Yu J, Zahn R, Wegmann F, et al. Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. *J Virol*. 2021 Mar 10;95(11):e00117-21.
- ⁴³ Shah P, Canziani GA, Carter EP, Chaiken I. The case for S2: The potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic. *Front Immunol*. 2021 Mar 9;12:637651
- ⁴⁴ Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature*. 2021;592:116-121.
- ⁴⁵ Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai, K, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. *Nat Commun*. 2021;12(1):848.
- ⁴⁶ Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon III KH, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science*. 2020;370:1464–1468.
- ⁴⁷ Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, et al., Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science*. 2021;373:1372–1377.
- ⁴⁸ Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination. *J Infect Dis*. 2015;212(12):1914-22.

⁴⁹ Schulte B, Marx B, Korencak M, Emmert D, Aldabbagh S, Eis-Hübinger AM, et al. Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses. *Front Med.* 2021 July 23; 8. Available from: <https://doi.org/10.3389/fmed.2021.704719>.

⁵⁰ Allen N, Brady M, Martin AIC, Domegan L, Walsh C, Doherty L, et al. Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individual. *J Infect.* 2021;83(4):e9-e10.

⁵¹ Movsisyan M, Chopikyan A, Kasparova I, Hakobjanyan G, Carrat F, Sukiasyan M, et al. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients. *Sci Rep.* 2022 July 20;12:12403.